Early insulinization to prevent diabetes progression

Diabetes Care

Volumn 36, Issue SUPPL.2, 2013, Pages

  Raz, Itamar ^a   Mosenzon, Ofri ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCOSE; INSULIN; METFORMIN; ROSIGLITAZONE; SULFONYLUREA;

CELL FUNCTION; CELL PROTECTION; COMPARATIVE STUDY; DISEASE COURSE; DRUG RESPONSE; EARLY INTERVENTION; GLUCOSE BLOOD LEVEL; GLUCOTOXICITY; GLYCEMIC CONTROL; HORMONE ACTION; HUMAN; HYPERGLYCEMIA; INSULIN TREATMENT; LIFESTYLE MODIFICATION; LIPOTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PATIENT ATTITUDE; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; TOXICITY;

DIABETES MELLITUS; DISEASE PROGRESSION; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN-SECRETING CELLS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS;

EID: 84891775266     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dcS13-2014     Document Type: Review

References (34)

1. Gerstein HC, Bosch J, Dagenais GR, et al.; ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012;367: 319-328
2. Unger RH, Grundy S. Hyperglycaemia as an inducer as well as a consequence of impaired islet cell function and insulin resistance: implications for the management of diabetes. Diabetologia 1985;28: 119-121
3. Poitout V, Robertson RP. Minireview: Secondary beta-cell failure in type 2 diabetesda convergence of glucotoxicity and lip-otoxicity. Endocrinology 2002;143:339-342
4. Poitout V, Robertson RP. Glucolipotox-icity: fuel excess and beta-cell dysfunction. Endocr Rev 2008;29:351-366
5. Poitout V, Amyot J, Semache M, Zarrouki B, Hagman D, Fontés G. Glucolipotoxicity of the pancreatic beta cell. Biochimic Bi-ophys Acta 2010; 1801:289-298
6. Weir GC, Marselli L, Marchetti P, Katsuta H, Jung MH, Bonner-Weir S. Towards better understanding of the contributions of overwork and glucotoxicity to the b-cell inadequacy of type 2 diabetes. Diabetes Obes Metab 2009;11(Suppl. 4):82-90
7. Cnop M. Fatty acids and glucolipotoxicity in the pathogenesis of Type 2 diabetes. Biochem Soc Trans 2008;36:348-352
8. Wajchenberg BL. b-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 2007;28:187-218
9. Rolla A. The pathophysiological basis for intensive insulin replacement. Int J Obes Relat Metab Disord 2004;28(Suppl. 2): S3-S7
10. Bonora E. Protection of pancreatic beta-cells: is it feasible? Nutr Metab Cardiovasc Dis 2008;18:74-83
11. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-1589
12. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012;55:1577-1596
13. IDF Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes. Brussels, International Diabetes Federation, 2005
14. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type2 diabetes mellitus:an algorithm for glycemic control. Endocr Pract 2009;15: 540-559
15. Berard LD, Booth G, Capes S, Quinn K, Woo V. Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Pharmacologic management of type 2 diabetes. Canadian J Diabetes 2008; 32:S53-S61
16. Home P, Mant J, Diaz J, Turner C; Guideline Development Group. Management of type 2 diabetes: summary of updated NICE guidance. BMJ 2008;336: 1306-1308
17. Kahn SE, Haffner SM, Heise MA, et al.; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or gly-buride monotherapy. N Engl J Med 2006; 355:2427-2443
18. Drucker DJ. Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. Mol Endocrinol 2003;17: 161-171
19. Bunck MC, Diamant M, Cornér A, et al. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care 2009;32:762-768
20. Garvey WT, Olefsky JM, Griffin J, Hamman RF, Kolterman OG. The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes 1985;34:222-234
21. Ilkova H, Glaser B, Tunçkale A, Bagriaçik N, Cerasi E. Induction of long-term gly-cemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Care 1997;20: 1353-1356
22. Park S, Choi SB. Induction of long-term normoglycemia without medication in Korean type 2 diabetes patients after continuous subcutaneous insulin infusion therapy. Diabetes Metab Res Rev 2003;19: 124-130
23. Ryan EA, Imes S, Wallace C. Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care 2004;27: 1028-1032
24. Li Y, Xu W, Liao Z, et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function. Diabetes Care 2004;27:2597-2602
25. Weng J, Li Y, Xu W, et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 2008;371:1753-1760
26. Chen H-S, Wu T-E, Jap T-S, Hsiao L-C, Lee S-H, Lin H-D. Beneficial effects of insulin on glycemic control and b-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia after short-term intensive insulin therapy. Diabetes Care 2008;31:1927-1932
27. Lingvay I, Legendre JL, Kaloyanova PF, Zhang S, Adams-Huet B, Raskin P. Insulin-based versus triple oral therapy for newly diagnosed type 2 diabetes: which is better? Diabetes Care 2009;32: 1789-1795
28. Kramer CK, Zinman B, Retnakaran R. Short-term intensive insulin therapy in type 2 diabetes mellitus: a systemic review and meta-analysis. Lancet Diabetes & Endocrinology. 30 January 2013 [Epub ahead of print]
29. Lingvay I, Kaloyanova PF, Adams-Huet B, Salinas K, Raskin P. Insulin as initial therapy in type 2 diabetes: effective, safe, and well accepted. J Investig Med 2007; 55:62-68
30. Harrison LB, Adams-Huet B, Raskin P, Lingvay I. b-Cell function preservation after 3.5 years of intensive diabetes therapy. Diabetes Care 2012;35:1406-1412
31. Mu PW, Chen YM, Lu HY, et al. Effects of a combination of oral anti-diabetes drugs with basal insulin therapy on b-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes. Diabetes Metab Res Rev 2012;28:236-240
32. Alvarsson M, Sundkvist G, Lager I, et al. Beneficial effects of insulin versus sul-phonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients. Diabetes Care 2003;26:2231-2237
33. Retnakaran R, Zinman B. Short-term intensified insulin treatment in type 2 diabetes: long-term effects on b-cell function. Diabetes Obes Metab 2012;14(Suppl. 3): 161-166
34. Chen A, Huang Z, Wan X, et al. Attitudes toward diabetes affect maintenance of drug-free remission in patients with newly diagnosed type 2 diabetes after short-term continuous subcutaneous insulin infusion treatment. Diabetes Care 2012;35:474-481